A Study to Understand the Distribution of Obesity Classes and Obesity Related Diseases in People With Obesity Across Countries in Czech Republic, Hungary and Poland

Obesity Clinical Trial

— ExplorEUEast  

Official title:

A Multicentre, Observational Study to Understand the Distribution of Obesity Classes and Obesity Related Comorbidities (ORCs) in People With Obesity Within a Real World Population in Czech Republic, Hungary and Poland

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05795166
• Other study ID #: DAS-7530
• Secondary ID: U1111-1277-8275
• Status: Completed
• Start date: April 28, 2023
• Est. completion date: November 30, 2023

Study information

• Verified date: April 2024
• Source: Novo Nordisk A/S
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The study is intended to understand the distribution of different obesity classes and obesity related diseases (diseases that present along with obesity) in patients with body mass index (BMI) ≥ 30 kg/m^2.

Participants will be asked to give information about their health. They will continue their normal way of life and will not get any medication or additional medical test other than those prescribed to you by their doctor. Participation in the study will last for about 1 day.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1241
• Est. completion date: November 30, 2023
• Est. primary completion date: April 28, 2023
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).

2. Male or female, age greater than or equal to 18 years at the time of inclusion/enrolment in the study.

3. BMI greater than or equal to 30 Kg/m^2 as measured at the inclusion in the study

Exclusion Criteria:

1. Previous participation in this study. Participation is defined as having given informed consent in this study.

2. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation as judged by physician.

Related Conditions & MeSH terms

• Obesity

Intervention

Other:
• No treatment given
No treatment given

Locations

Country	Name	City	State
Czechia	ADMED s.r.o.	Ceske Budejovice
Czechia	Ordinace Hradebni s r o	Ceske Budejovice
Czechia	Poliklinika Chocen a.s.	Chocen
Czechia	PRAKTIK HRADEK s.r.o.	Hradek Nad Nisou
Czechia	MUDr Jakub Strincl s r o	Liberec
Czechia	Res Medica s r o	Novy Knin
Czechia	Zdravi-fit s.r.o.	Praha 5
Czechia	Prakticky lekar Vsestary s r o	Vsestary
Hungary	Dr. Dozsa Katalin Maria EV	Biatorbágy
Hungary	Dr. Peter Abel Perjes Practice	Bicske
Hungary	Dr. Torzsa Peter Bt.	Budapest
Hungary	Family doctors office on Queen Elizabeth Street	Budapest
Hungary	A & P Kft.	Hosszuheteny
Hungary	DRC Szentendre	Szentendre
Hungary	Pecsi Tudomanyegyetem	Szentlorinc
Hungary	Co-Medi-Catus Kft.	Szigethalom
Poland	Akademicka Praktyka Medycyny Rodzinnej Bielska Chlabicz Czarnowski Oltarzewska Sawicka Powierza	Bialystok
Poland	Centrum Medyczne Pratia Bydgoszcz	Bydgoszcz
Poland	Niepuliczny Zaklad Opieki Zdrowotnej	Gizycko
Poland	Niepubliczny Zaklad Opieki Zdrowotnej NZOZ ESKULAP s c	Koluszki
Poland	Bellus Przychodnia Lekarza Rodzinnego	Ksiaz Wielkopolski
Poland	Aloes sp. z.o. o	Lodz
Poland	Santa Familia Centrum Badan, Profilaktyki i Leczenia	Lodz
Poland	Samodzielny Publiczny Szpital kliniczny Nr 4 w Lublinie	Lublin
Poland	ALLMEDICA sp. z o. o.	Nowy Targ
Poland	FutureMeds Olsztyn	Olsztyn
Poland	Clinmedica Research spzo.o	Skierniewice
Poland	DC-MED	Swidnica
Poland	ETG Warszawa	Warszawa
Poland	Przychodnia Vistamed	Wroclaw

Sponsors (1)

Lead Sponsor	Collaborator
Novo Nordisk A/S

Countries where clinical trial is conducted

Czechia,  Hungary,  Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of patients with at least one obesity related comorbidity of interest for obesity classes I, II and III pooled across all countries	% patients with obesity	At the time of enrolment (Day 1)